Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The treatment of Crohn’s disease ( CD ) includes not only conventional therapies, many of which are generically available, but also potent biologics, which are often reserved for patients with moderate to severe disease activity. In addition to the entrenched TNF -ɑ inhibitors, two newer biologics (Takeda’s Entyvio and, mostrecently, Janssen’s Stelara) are being used primarily in the TNF -refractory population and competing with the older biologics for earlier lines of therapy. Given this increasing competition, which will continue to intensify as additional agents launch, brand differentiation, insight into the current clinical profiles and cost basis of patients taking available brands, and identification of growth opportunities in key patient segments will be critical for market success.
What is the patient share in CD of the biologics (, AbbVie’s Humira, Janssen’s Remicade, Entyvio) and other key segments?
What are the demographic characteristics and clinical profiles of CD patients taking Humira, Remicade, Entyvio, Stelara, and other key agents?
What are the key risk factors, comorbidities, and co-prescribed therapies by patient segment for CD ?
How do patient cohorts in CD compare in care utilization and outcomes (physician visits and other healthcare encounters)?
What type of insurance do CD patients have?
What are the reimbursed and out-of-pocket costs of the biologics and other key CD brands? What level of discounting exists between the provider charge and the payer-reimbursed amount, by agent?